These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 28109295)

  • 1. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N; Rosenstock J; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Espeland MA; Bluhmki E; Mattheus M; Ryckaert B; Patel S; Johansen OE; Woerle HJ
    Diab Vasc Dis Res; 2015 May; 12(3):164-74. PubMed ID: 25780262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
    Tripolt NJ; Aberer F; Riedl R; Url J; Dimsity G; Meinitzer A; Stojakovic T; Aziz F; Hödl R; Brachtl G; Strunk D; Brodmann M; Hafner F; Sourij H
    Cardiovasc Diabetol; 2018 May; 17(1):71. PubMed ID: 29773079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
    Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial.
    Tripolt NJ; Aberer F; Riedl R; Hutz B; Url J; Dimsity G; Meinitzer A; Stojakovic T; Hödl R; Brodmann M; Hafner F; Sourij H
    Trials; 2016 Oct; 17(1):495. PubMed ID: 27733180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
    Kraaijenhof J; Muskiet MHA; Tonneijck L; Ouwens DM; Kramer MHH; van Raalte DH; Smits MM
    Diabetes Obes Metab; 2020 Oct; 22(10):1847-1856. PubMed ID: 32476255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
    Leung M; Leung DY; Wong VW
    Diab Vasc Dis Res; 2016 May; 13(3):236-43. PubMed ID: 26993495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
    Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Danser AHJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2022 Jan; 24(1):115-124. PubMed ID: 34580975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 11. Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial.
    Sidelmann Christensen A; Storgaard H; Hædersdal S; Hansen T; Knop FK; Vilsbøll T
    BMJ Open; 2018 Oct; 8(10):e022517. PubMed ID: 30287671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR; Swallow R; Dugi KA; Woerle HJ
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
    Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Touw DJ; Danser AHJ; Joles JA; van Raalte DH
    Diabetes Care; 2020 Nov; 43(11):2889-2893. PubMed ID: 32900785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
    Awal HB; Nandula SR; Domingues CC; Dore FJ; Kundu N; Brichacek B; Fakhri M; Elzarki A; Ahmadi N; Safai S; Fosso M; Amdur RL; Sen S
    Cardiovasc Diabetol; 2020 Jun; 19(1):72. PubMed ID: 32493344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.